For the year ending 2025-12-31, MNKD had $28,551K increase in cash & cash equivalents over the period. $13,689K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 5,863 |
| Stock-based compensation | 24,195 |
| Interest on liability for sale of future royalties | 14,449 |
| Sold portion of royalty revenue | 12,811 |
| Write-off of inventory | 10,397 |
| Depreciation and amortization | 12,284 |
| Loss (gain) on foreign currency transaction | -7,749 |
| Impairment loss on available-for-sale investment | -6,409 |
| Net accretion of investments | -2,647 |
| Non-cash lease expense of right-of-use assets | 1,212 |
| Change in fair value of contingent liability | 1,029 |
| Amortization of debt discount and issuance costs | 854 |
| Other, net | -155 |
| Change in deferred tax liability | -4,969 |
| Accounts receivable, net | 4,762 |
| Inventory | 6,624 |
| Prepaid expenses and other current assets | 10,032 |
| Other assets | 1,909 |
| Accounts payable | -16,711 |
| Accrued expenses and other current liabilities | 3,256 |
| Deferred revenue | -8,259 |
| Operating lease liabilities | -873 |
| Net cash provided by operating activities | 18,255 |
| Purchase of available-for-sale securities | 157,803 |
| Proceeds from maturities of available-for-sale securities | 215,308 |
| Acquisition of scpharma, net of cash acquired | 347,742 |
| Issuance of note receivable | 10,000 |
| Purchase of property and equipment | 4,566 |
| Net cash used in investing activities | -304,803 |
| Proceeds from term loan | 325,000 |
| Payment of loan issuance costs | 7,266 |
| Payments for taxes related to net issuance of common stock associated with restricted stock units and stock options | 3,262 |
| Principal payments on financing liability | 726 |
| Proceeds from market price stock purchase plan and employee stock purchase plan | 1,992 |
| Milestone right agreement payment | 639 |
| Net cash provided by (used in) financing activities | 315,099 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 28,551 |
| Cash, cash equivalents and restricted cash, beginning of period | 47,076 |
| Cash, cash equivalents and restricted cash, end of period | 75,627 |
MANNKIND CORP (MNKD)
MANNKIND CORP (MNKD)